Oncologic progression of bone plasmacytomas to multiple myeloma

Detalhes bibliográficos
Autor(a) principal: Bertanha, Fernanda
Data de Publicação: 2006
Outros Autores: Boufelli, Gabriela, Camargo, Olavo Pires de, Baptista, André Mathias, Caiero, Marcelo Tadeu, Oliveira, Claudia Regina GCM de, Filippi, Renée
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/17523
Resumo: PURPOSE: To evaluate the clinical aspects, diagnoses, prognostic factors, and percent progression of plasmacytoma to multiple myeloma. MATERIALS AND METHODS: 103 medical records of patients suspected of plasmacytoma were surveyed covering the period between 1950 and 1998, and 30 were selected for analysis. Patients were classified into 2 groups: patients who did (n = 17) and did not (n = 13) progress to multiple myeloma. Comparative statistics regarding a variety of clincial aspects were developed. RESULTS: Patients who progressed to multiple myeloma were younger than those who did not (52.3 ± 2.6 vs 62.6 ± 3.4 years; mean ± SEM; P = 0.02). There were no significant differences in gender between groups. A higher incidence of multiple recurrence was observed in patients who progressed to multiple myeloma (75%, P = 0.049). Both groups showed a prevalence of vertebral column injuries. No significant differences were found between groups regarding the disease period (from the onset of symptoms until diagnosis) (P = 0.20) and survival (P = 0.34). The average time to progression from plasmacytoma to myeloma was 41 ± 39 months (mean ± SD), and the progression rate was 57%. CONCLUSION: Patients who progressed to multiple myeloma were younger than those who did not. No significant differences were found between groups regarding sex, time from symptom onset to diagnosis, and survival time. In both groups, the most affected anatomic location was the vertebral column, and most affected sex was male. The average time to progression to multiple myeloma was 41 months. It was not possible to determine the factors that influenced the survival of patients with plasmacytoma or for those who progressed to multiple myeloma.
id USP-19_59f4c0e019e4c393cc0d670159f44901
oai_identifier_str oai:revistas.usp.br:article/17523
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling Oncologic progression of bone plasmacytomas to multiple myeloma Evolução oncológica dos plasmocitomas ósseos para mieloma múltiplo PlasmocitomaMieloma MúltiploEvolução clínicaPrognósticoCélulas plasmáticasPlasmacytomaMultiple myelomaClinical progressionPrognosisPlasma cells PURPOSE: To evaluate the clinical aspects, diagnoses, prognostic factors, and percent progression of plasmacytoma to multiple myeloma. MATERIALS AND METHODS: 103 medical records of patients suspected of plasmacytoma were surveyed covering the period between 1950 and 1998, and 30 were selected for analysis. Patients were classified into 2 groups: patients who did (n = 17) and did not (n = 13) progress to multiple myeloma. Comparative statistics regarding a variety of clincial aspects were developed. RESULTS: Patients who progressed to multiple myeloma were younger than those who did not (52.3 ± 2.6 vs 62.6 ± 3.4 years; mean ± SEM; P = 0.02). There were no significant differences in gender between groups. A higher incidence of multiple recurrence was observed in patients who progressed to multiple myeloma (75%, P = 0.049). Both groups showed a prevalence of vertebral column injuries. No significant differences were found between groups regarding the disease period (from the onset of symptoms until diagnosis) (P = 0.20) and survival (P = 0.34). The average time to progression from plasmacytoma to myeloma was 41 ± 39 months (mean ± SD), and the progression rate was 57%. CONCLUSION: Patients who progressed to multiple myeloma were younger than those who did not. No significant differences were found between groups regarding sex, time from symptom onset to diagnosis, and survival time. In both groups, the most affected anatomic location was the vertebral column, and most affected sex was male. The average time to progression to multiple myeloma was 41 months. It was not possible to determine the factors that influenced the survival of patients with plasmacytoma or for those who progressed to multiple myeloma. OBJETIVO: Avaliar os aspectos clínicos, diagnósticos, fatores de prognóstico e porcentagem de evolução dos casos de plasmocitoma para mieloma múltiplo. MATERIAS E MÉTODOS: Foram levantados 103 prontuários do Hospital das Clínicas da FMUSP, entre os anos de 1950 e 1998. Destes, 73 não foram utilizados por perda de seguimento ou por apresentarem diagnóstico diferente de plasmocitoma. RESULTADOS: Concluímos que a idade dos pacientes que evoluíram para mieloma múltiplo é inferior a dos pacientes que não evoluíram. A média do primeiro grupo foi de 52,3 ± 2,6 anos e a do segundo 62,6 ± 3,4 anos (média ± SEM; p=0,02). Não houve diferença estatística quanto ao sexo. Analisando pacientes com plasmocitoma que evoluiu para mieloma múltiplo, foi observada uma incidência maior de recidivas múltiplas (75%, p=0,049). Em ambos os grupos houve predominância de lesões da coluna vertebral. Não houve nenhuma diferença significativa entre os grupos com relação ao tempo de doença (desde o aparecimento dos sintomas até o diagnóstico) (p=0,20) e à sobrevida (p=0,34). Quanto ao tempo de evolução de plasmocitoma para mieloma, a média foi de 41 meses (DP=38,8), com uma taxa de evolução aproximadamente igual a 57%. CONCLUSÃO: Os pacientes que evoluíram para mieloma múltiplo são mais jovens. Não houve diferença significativa entre os dois grupos quanto ao sexo, tempo de doença e tempo de sobrevida. Em ambos os grupos a localização anatômica mais acometida foi a coluna vertebral. O tempo médio de evolução para mieloma múltiplo foi de 41 meses. Não foi possível calcular os fatores que influem na sobrevida dos pacientes com plasmocitoma e dos pacientes com plasmocitoma que evoluiu para mieloma múltiplo. Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2006-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/1752310.1590/S1807-59322006000200009Clinics; v. 61 n. 2 (2006); 139-146 Clinics; Vol. 61 Núm. 2 (2006); 139-146 Clinics; Vol. 61 No. 2 (2006); 139-146 1980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/17523/19581Bertanha, FernandaBoufelli, GabrielaCamargo, Olavo Pires deBaptista, André MathiasCaiero, Marcelo TadeuOliveira, Claudia Regina GCM deFilippi, Renéeinfo:eu-repo/semantics/openAccess2012-05-22T18:06:15Zoai:revistas.usp.br:article/17523Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2012-05-22T18:06:15Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Oncologic progression of bone plasmacytomas to multiple myeloma
Evolução oncológica dos plasmocitomas ósseos para mieloma múltiplo
title Oncologic progression of bone plasmacytomas to multiple myeloma
spellingShingle Oncologic progression of bone plasmacytomas to multiple myeloma
Bertanha, Fernanda
Plasmocitoma
Mieloma Múltiplo
Evolução clínica
Prognóstico
Células plasmáticas
Plasmacytoma
Multiple myeloma
Clinical progression
Prognosis
Plasma cells
title_short Oncologic progression of bone plasmacytomas to multiple myeloma
title_full Oncologic progression of bone plasmacytomas to multiple myeloma
title_fullStr Oncologic progression of bone plasmacytomas to multiple myeloma
title_full_unstemmed Oncologic progression of bone plasmacytomas to multiple myeloma
title_sort Oncologic progression of bone plasmacytomas to multiple myeloma
author Bertanha, Fernanda
author_facet Bertanha, Fernanda
Boufelli, Gabriela
Camargo, Olavo Pires de
Baptista, André Mathias
Caiero, Marcelo Tadeu
Oliveira, Claudia Regina GCM de
Filippi, Renée
author_role author
author2 Boufelli, Gabriela
Camargo, Olavo Pires de
Baptista, André Mathias
Caiero, Marcelo Tadeu
Oliveira, Claudia Regina GCM de
Filippi, Renée
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Bertanha, Fernanda
Boufelli, Gabriela
Camargo, Olavo Pires de
Baptista, André Mathias
Caiero, Marcelo Tadeu
Oliveira, Claudia Regina GCM de
Filippi, Renée
dc.subject.por.fl_str_mv Plasmocitoma
Mieloma Múltiplo
Evolução clínica
Prognóstico
Células plasmáticas
Plasmacytoma
Multiple myeloma
Clinical progression
Prognosis
Plasma cells
topic Plasmocitoma
Mieloma Múltiplo
Evolução clínica
Prognóstico
Células plasmáticas
Plasmacytoma
Multiple myeloma
Clinical progression
Prognosis
Plasma cells
description PURPOSE: To evaluate the clinical aspects, diagnoses, prognostic factors, and percent progression of plasmacytoma to multiple myeloma. MATERIALS AND METHODS: 103 medical records of patients suspected of plasmacytoma were surveyed covering the period between 1950 and 1998, and 30 were selected for analysis. Patients were classified into 2 groups: patients who did (n = 17) and did not (n = 13) progress to multiple myeloma. Comparative statistics regarding a variety of clincial aspects were developed. RESULTS: Patients who progressed to multiple myeloma were younger than those who did not (52.3 ± 2.6 vs 62.6 ± 3.4 years; mean ± SEM; P = 0.02). There were no significant differences in gender between groups. A higher incidence of multiple recurrence was observed in patients who progressed to multiple myeloma (75%, P = 0.049). Both groups showed a prevalence of vertebral column injuries. No significant differences were found between groups regarding the disease period (from the onset of symptoms until diagnosis) (P = 0.20) and survival (P = 0.34). The average time to progression from plasmacytoma to myeloma was 41 ± 39 months (mean ± SD), and the progression rate was 57%. CONCLUSION: Patients who progressed to multiple myeloma were younger than those who did not. No significant differences were found between groups regarding sex, time from symptom onset to diagnosis, and survival time. In both groups, the most affected anatomic location was the vertebral column, and most affected sex was male. The average time to progression to multiple myeloma was 41 months. It was not possible to determine the factors that influenced the survival of patients with plasmacytoma or for those who progressed to multiple myeloma.
publishDate 2006
dc.date.none.fl_str_mv 2006-04-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/17523
10.1590/S1807-59322006000200009
url https://www.revistas.usp.br/clinics/article/view/17523
identifier_str_mv 10.1590/S1807-59322006000200009
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/17523/19581
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; v. 61 n. 2 (2006); 139-146
Clinics; Vol. 61 Núm. 2 (2006); 139-146
Clinics; Vol. 61 No. 2 (2006); 139-146
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1787713167757934592